Methodology: 3.5/5
Usefulness: 3/5

Ruberto AJ, et al. Ann Emerg Med. 2020 Nov 5:S0196-0644(20)30666-1

Question and Methods: Randomized control trial in which cannabis users with active emesis received either haloperidol (0.05mg/kg or 0.1 mg/kg IV) or ondansetron 8mg IV for symptomatic relief.
Findings: 33 patients were enrolled and randomized, and for the primary outcome haloperidol (either dose) was superior to ondansetron [Difference 2.3 cm (95% confidence 0.6-4.0cm); P=0.01].
Limitations: This study had several limitations including complex design, enrollment difficulties, unplanned interim analyses, and unclear presentation of results.

Interpretation: In patients with suspected CHS, lower dose haloperidol (0.05 mg/kg) can be considered as first line supportive therapy in the ED. 

By: Dr. Zachary Macdonald


  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, assistant professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts